The estimated Net Worth of George Harrison Talbot is at least $137 mil dollars as of 31 July 2018. George Talbot owns over 14,500 units of Nabriva Therapeutics Plc stock worth over $67,649 and over the last 8 years he sold NBRV stock worth over $69,787. In addition, he makes $0 as Independent member of the Supervisory Board at Nabriva Therapeutics Plc.
Sign up
George Talbot NBRV stock SEC Form 4 insiders trading
George has made over 4 trades of the Nabriva Therapeutics Plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 14,500 units of NBRV stock worth $39,875 on 31 July 2018.
The largest trade he's ever made was buying 14,500 units of Nabriva Therapeutics Plc stock on 31 July 2018 worth over $39,875. On average, George trades about 1,521 units every 43 days since 2017. As of 31 July 2018 he still owns at least 47,640 units of Nabriva Therapeutics Plc stock.
You can see the complete history of George Talbot stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
George Talbot biography
DR. George H. Talbot M.D. serves as Independent member of the Supervisory Board of the Company. Dr. Talbot previously served on the supervisory board of Nabriva Austria from 2009 until the Redomiciliation. Dr. Talbot has been the principal at Talbot Advisors LLC, a biopharmaceutical company consultancy, since 2007 and prior to that, from 2000 to 2006. From 2006 to 2007, he served as chief medical officer and executive vice president of Cerexa, Inc. prior to its acquisition by Forest Laboratories, Inc. Dr. Talbot also worked closely with Calixa Therapeutics, Inc. and Durata Therapeutics, Inc. prior to their acquisitions by Cubist Pharmaceuticals, Inc. and Actavis plc, respectively. He was an initial member of the Infectious Diseases Society of America's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs") and recently completed a seven-year tenure as co-chair of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Projects for Endpoint Development in Acute Bacterial Skin and Skin Structure Infections, Community-acquired Bacterial Pneumonia, and Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia, which made evidence-based recommendations to the Food and Drug Administration for its Guidance development in these indications. Dr. Talbot received his B.A. from Wesleyan University, his M.D. from the Yale University School of Medicine, and his Infectious Diseases fellowship training at the University of Pennsylvania. After serving as a faculty member of the Infectious Diseases Section at the University of Pennsylvania, he joined the anti-infectives group at Rhone-Poulenc-Rorer in 1990. Talbot is qualified to serve as a director due to his education, training and extensive experience in the biopharmaceutical industry.
How old is George Talbot?
George Talbot is 72, he's been the Independent member of the Supervisory Board of Nabriva Therapeutics Plc since 2018. There are no older and 17 younger executives at Nabriva Therapeutics Plc.
What's George Talbot's mailing address?
George's mailing address filed with the SEC is 1000 Continental Dr #600, King of Prussia, PA 19406, USA.
Insiders trading at Nabriva Therapeutics Plc
Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over $3,221,169 worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth $1,215,585 . The most active insiders traders include Capital Viii, Llc Vivo, Bioventures Cayman Ltd Hbm y Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of $23,562. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth $2,155.
What does Nabriva Therapeutics Plc do?
nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo
What does Nabriva Therapeutics Plc's logo look like?
Complete history of George Talbot stock trades at Nabriva Therapeutics Plc
Nabriva Therapeutics Plc executives and stock owners
Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Colin Broom,
Director -
Theodore Schroeder,
Chief Executive Officer, Director -
Steven Gelone,
President, Chief Operating Officer -
Francesco Lavino,
Chief Commercial Officer -
Gary Sender,
Chief Financial Officer -
Jennifer Schranz,
Chief Medical Officer -
Theodore R. Schroeder,
CEO & Director -
Dr. Steven P. Gelone Pharm. D,
Pres, COO & Director -
Dr. Colin Broom M.D.,
Director -
Stephen Webster,
Independent Member of the Supervisory Board -
George Talbot,
Independent member of the Supervisory Board -
Charles Rowland,
Independent Member of the Supervisory Board -
Carrie Bourdow,
Independent Member of the Supervisory Board -
Robert Crotty,
General Counsel, Secretary -
Daniel Burgess,
Independent Chairman of the Supervisory Board -
Werner Heilmayer,
VP of CMC & IP -
Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H.,
Chief Medical Officer -
Gary L. Sender,
Consultant -
Jodi VanDerveer,
Sr. VP & Head of HR -
J. Christopher Naftzger BA, Esq., J.D.,
Gen. Counsel -
Daniel Dolan,
Chief Financial Officer -
Bioventures Cayman Ltd Hbm,
10% owner -
Elyse G. Seltzer,
Chief Medical Officer -
J. Christopher Naftzger,
General Counsel and Corp Sec -
Capital Viii, Llc Vivo,
10% owner -
Mark Corrigan,
Director -
Christine J. Guico Pabia,
Chief Medical Officer -
Daniel Dolan,
Chief Financial Officer -
Lisa Dalton,
Director